29th Napa Pain Conference Posters
Aug 18, 2022 ‐ Aug 20, 2022
Products
Preview Available
Post Dural Puncture Headache After Removal of Spinal Cord Stimulator Leads: A Case Report
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
Post dural puncture headaches are, more recently, being documented as a complication related to spinal cord stimulator placement. Dural compromise are usually appreciated prior to this condition's onset. A viable treatment for post dural headaches is epidural blood patches. Less reported in literature still, is the presence of post dural headache after leads removal from a trail spinal cord stimulator, when initial placement of the spinal cord stimulator was without noted dural compromise and tolerated by the patient well prior to its removal.
Disclosures
Nothing to Disclose by any Author
Speaker(s):- Dr. Gurtej S. Bajaj, MD, Hospital of the University of Pennsylvania
- Ignacio Badiola, Hospital of the University of Pennsylvania
- Russell Bell, Hospital of the University of Pennsylvania
- Warren Southerland, Hospital of the University of Pennsylvania
Preview Available
A self-anchoring injectable helical wire rope structure electrode (Injectrode) enables ease of placement and clear imaging
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
In order to overcome barriers to adoption of neurostimulation technologies by patients and clinicians, we present here a minimally invasive needle placeable and fully implanted neurostimulator that is suitable for clinical imaging (U/S, X-Ray, MRI). The structural design and placement procedure of the injectable helical wire structure electrode (Injectrode) renders the device self anchoring and deliverable using a minimal number of components. Demonstrated are placements by clinicians on various nerve targets in animal and human models.
Disclosures
- Stephan Nieuwoudt is employed by and owns equity in Neuronoff, Inc.
- Amelia Howe is employed by and owns equity in Neuronoff, Inc.
- Johanna Pearson is employed by Neuronoff, Inc.
- Emily Szabo is employed by and owns equity in Neuronoff, Inc.
- Morgan McGaughey is employed by and owns equity in Neuronoff, Inc.
- Derrick Liu is employed by and owns equity in Neuronoff, Inc.
- Shaher Ahmad is employed by and owns equity in Neuronoff, Inc.
- Kip A. Ludwig is receiving funds from and owns equity in Neuronoff, Inc.
- Hesham Elsharkawy owns equity in Neuronoff, Inc.
- Amol Soin owns equity in Neuronoff, Inc.
- Alaa Abd-Elsayed owns equity in Neuronoff, Inc.
- Manfred Franke is employed by and owns equity in Neuronoff, Inc.
- Andrew J. Shoffstall is receiving funds from and owns equity in Neuronoff, Inc.
- This project is supported by Neuronoff Inc., NIH 1U18EB029251-01 Grant, and the DARPA EEI program. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or the National Institutes of Health.
- Stephan Nieuwoudt, PhD, Director of Research and Development, Neuronoff, Inc
- Amelia Howe, Research Scientist, Neuronoff, Inc.
- Johanna Pearson, Research Intern, Neuronoff, Inc.
- Elizabeth Ingram, MRI Technologist, Department of Radiology, University of Alabama at Birmingham
- Emily Szabo, Technical Writer, Manufacturing Engineer, Neuronoff, Inc.
- Derrick Liu, MS, Sr. Research Scientist, Neuronoff, Inc.
- Morgan McGaughey, Jr. Clinical & Development Scientist, Neuronoff, Inc.
- Shaher Ahmad, COO, Neuronoff, Inc.
- Mark Bolding, Associate Professor, Department of Radiology, University of Alabama at Birmingham
- Kip Ludwig, PhD, Co-Director, Wisconsin Institute for Translational Neuroengineering (WITNe)
- Hesham Elsharkawy, Director of Transitional Pain Service, MetroHealth
- Amol Soin, Director, Ohio Pain Clinic
- Alaa Abd-Elsayed, Medical Director, Pain Clinic, Anesthesiology Department and Pain Medicine, University of Wisconsin School of Medicine and Public Health
- Manfred Franke, PhD, CEO, Neuronoff, Inc
- Andrew J. Shoffstall, Assistant Professor, Dept. of Biomedical Engineering, Case Western Reserve University
Multimodal Imaging Analysis of Fibromyalgia Syndrome Reveals Structural and Functional Abnormalities in Cortico-Thalamic Loops
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
Here we propose a characterization of Fibromyalgia pathophysiology in gray matter (GM) tissue using a multimodal neuroimaging approach (volumetric, diffusion-weighted, and resting-state functional connectivity).
Disclosures
Nothing to Disclose by any Author
Speaker(s):- Andrew D. Geoly, MS, Stanford University
- Ryan T. Ash, PhD, Stanford University
- Dr. Mahendra Bhati, MD, Clinical Professor, Psychiatry and Behavioral Sciences, Stanford University
- Dr. Charles DeBattista, MD, Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult), Stanford Wu Tsai Neurosciences Institute
- Flint M. Espil, MD, Stanford University
- Nimrod Y. Keynan, PhD, Stanford University
- Ian H. Kratter, PhD, Stanford University
- Kristin S. Raj, MD, Stanford University
- Gregory L. Sahlem, MD, Stanford University
- Malvika Sridhar, MS, Stanford University
- Dr. Nolan R. Williams, MD, Director of the Stanford Brain Stimulation Lab, Stanford Hospital and Clinics
Mechanistic Insights into Anterolateral System Modulation with Conventional and Burst Stimulation
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
Evoked compound action potentials (ECAPs) from both the dorsal columns and the anterolateral system (ALS) in sheep were used to quantify neural activation with burst and conventional spinal cord stimulation (SCS). When dosed equivalently, no statistically significant difference in neural activation was noted between both stimulation modalities. Sub-threshold SCS resulted in no change in neural activation, while supra-threshold SCS potentiated ALS excitability in an equivalent manner for both modalities. We postulate that differences noted previously between burst and conventional SCS results from non-equivalent dosing between these stimulation modalities.
Disclosures
- Authors Dinsmoor and Usoro are employees of Medtronic plc.
- Author Poree has stock options in Nalu, and has received research funding from Abbott, Nalu, and Saluda; he is a consultant for Nalu, Saluda, and Medtronic.
- This work was funded by Medtronic plc.
- David Dinsmoor, MS, Distinguished Engineer, Medtronic
- Dr. Lawrence Poree, MD, PhD. MPH, Clinical Professor, Department of Anesthesia, University of California at San Francisco (UCSF)
- Joshua Usoro, Senior Biomedical Engineer, Medtronic
Human Transcription Error Assessment within a Simulated Electronic Health Record System
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
Medical practices and hospitals have adopted Electronic Health Record (EHR) systems that streamline patient information and relevant clinical data. Access to an EHR system with effective exchange of electronic health information is critical in maintaining data consistency and reliability. Human errors that occur during the transcription of data from one field to another, or from a paper to an electronic record, can negatively impact patient care and reduce efficiency. Human transcription errors can occur as early as the scheduling process, with these errors compounding as more individuals touch and re-transcribe the data. Though previous literature have touched upon error rates, they have not addressed the complexity of patient data involved with scheduling.
Disclosures
Nothing to Disclose by any Author
Speaker(s):- Dr. Timothy T. Davis, MD, Medical Director, CEO, Founder, Source Healthcare
- Terry Nguyen, Clinical Research Coordinator, Source Healthcare
- Tony Ong, Clinical Research Coordinator, Source Healthcare
- Stephanie Jones, Administrator, Source Healthcare
Atypical Presentation of Post-Dural Puncture Headache from Cervical Spinal Cord Stimulator Lead Placement
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
The incidence of Post Dural Puncture Headaches (PDPH) is less than 1% with the use of fluoroscopy. PDPH typically occurs due to accidental dural puncture during initial epidural needle placement. We present a case of a 44 year-old male with history of aplastic anemia who presented with bilateral hand and lower extremity paresthesia with severe allodynia refractory to treatment. The patient experienced significant relief of symptoms after dual thoracic and single cervical SCS lead placement He presented with slow-onset headache after three days from cervical lead tip puncture. To date, there is a paucity of papers describing such an occurrence.
Disclosures
Nothing to disclose by any author
Speaker(s):- Dr. Joysree Subramanian, MD, Associate Professor and Medical Director, OU Health Pain Medicine
- Dr. Cooper Yates, MD, Pain Medicine Fellow, OU Health Pain Medicine
Preview Available
18 Month Outcomes from Multicenter RCT: Spinal Cord Stimulation at 10kHz for Non-Surgical Refractory Back Pain
Aug 21, 2022 3:00pm ‐ Aug 21, 2022 3:00pm
Synopsis
Spinal cord stimulation (SCS) is primarily used to treat persistent back and leg pain following spine surgery, but minimal evidence existed to show efficacy in patients who were surgery naïve. This randomized controlled trial was designed to demonstrate the clinical efficacy of 10kHz SCS in chronic back pain patients who were surgery naïve and not acceptable candidates for surgery. Recently published 12-month results showed profound improvements in pain relief, function, and quality of life with 10kHz SCS over conventional medical management for non-surgical refractory back pain (NSRBP) patients. We now report 18-month results demonstrating the durability of these therapeutic outcomes.
Disclosures
- Taissa Cherry, MD has contracted research with Nevro Corp, with all funds going to her institution
- Jessica Jameson, MD receives consulting and speaking fees from Nevro, Boston Scientific
- Naresh P. Patel, MD has contracted research with Nevro Corp, with all funds going to his institution
- Curtis Johnson, MD has contracted research with Nevro Corp
- Daniel Kloster, MD has contracted research with Nevro Corp
- Aaron K. Calodney, MD AC receives consulting fees from Nevro Corp.
- Rose Province-Azalde, MS Employee of Nevro Corp.
- Leonardo Kapural, MD, PhD on scientific advisory board for Abbott, Nevro, Saluda, SPR therapeutics, Neuros, Halyard. Is a consultant: Gimer Medical, Best Doctors, Solis Medical, Nalu Medical, Biotronik, Nevro, and has research contracts with Stimwave, Nevro, Neuros, Halyard, SPR therapeutics, Boston Scientific, Medtronic, Saluda.
- Dr. Taissa Cherry, MD, Director, Interventional Pain Medicine, Kaiser Redwood City
- Jessica Jameson, MD, Interventional Pain Management Physician, Axis Spine Center
- Naresh P. Patel, MD, Neurosurgeon, Mayo Clinic Phoenix
- Curtis Johnson, MD, Pain Management, Midwest Pain Management Center
- Daniel Kloster, MD, Pain Management Specialist, Crimson Pain Management
- Dr. Aaron K. Calodney, MD, DABA, FASA, FIPP, ABIPP, Director of Clinical Research, Precision Spine Care
- Dr. Leonardo Kapural, MD, PhD, Pain Physician, Carolinas Pain Institute and The Center for Clinical Research
- Rose Azalde